

CLINICAL VIGNETTE

Psoriasis: Medications and Other Environmental Factors

By Brian S. Morris, MD

Case Report

The patient is a 64-year-old male with a history of psoriasis, hyperlipidemia, hypertension, and type-2 diabetes, who presented to the office with worsening psoriasis over the past week. His back and knees have been more swollen and painful and his psoriatic rash worsened on the extensor surfaces of his elbows and knees and trunk. He had eaten more seafood lately to reduce his saturated fat intake and also increased his omega-3 fatty acids. Two weeks ago he went to urgent care with an upper respiratory infection and was treated with azithromycin. His cardiologist also increased his dose of carvedilol from 3.125 mg to 6.25 mg twice daily last month.

Past medical history also includes osteoarthritis, GERD, spinal stenosis and asthma. Medications include etanercept, Metformin, Atorvastatin, Pantoprazole, Losartan, Tamsulosin, Ethacrynic acid, Carvedilol, and Naprosyn. Allergies include Penicillin, Sulfa-containing antibiotics, and systemic steroids.

He is a non-smoker who has 1-2 drinks per week. His alcohol intake increased lately due to work stress. He exercises regularly using an elliptical trainer and spends most of his time indoors. Family history is negative for psoriasis, and remarkable for parents with hypertension, and a sister with type-2 diabetes.

Physical examination revealed a height of 5 foot 10 inches, weight 217 pounds, BMI of 31, blood pressure 126/86, pulse 64 and normal temperature. His examination was normal except for an impressive scaly erythematous rash on the back and extensor surfaces of his extremities and swollen, inflamed knees.

Labs included normal CBC, chemistries, ESR, thyroid, creatine kinase, and lipid panel.

Psoriasis is a chronic multisystem autoimmune disease that typically presents with dermatologic and/or rheumatologic manifestations¹. Psoriasis is very common, affecting 2-4% of the population in the United States². A large percentage of patients with

psoriasis have other disorders such as type-2 diabetes, hypertension, and hyperlipidemia and take multiple prescription medications³. In some studies, 25% of patients with psoriasis were taking three or more prescription medications⁴. Although no definitive causal relationship has been established, evidence suggests certain medications, smoking, bacterial and viral infections, alcohol consumption, obesity, trauma, stress, and other environmental exposures can contribute to psoriasis⁵. One study reported approximately 83% of psoriatic exacerbations were related to medications⁶.

Environmental exposures impact the expression of psoriasis several ways: exacerbating currently active psoriasis; triggering previously unexpressed psoriasis; or causing a drug-eruption mimicking psoriasis⁷. These manifestations can present with all of the various dermatologic forms of psoriasis including the less common pustular psoriasis⁸. In addition to the nails, non-dermatologic systems can also be affected including the joints⁷. Environmental factors may affect psoriasis through both immunologic and non-immunologic mechanisms which are complex in nature and appear to be mediated by t-cells and interleukins in the dermis⁸. In addition, these factors can trigger a new psoriatic reaction or aggravate a pre-existing psoriasis⁹. Medications are the common triggers including beta-blockers, antibiotics, and nonsteroidal anti-inflammatory drugs (NSAIDs) and diet is also a common trigger¹⁰.

Beta blockers are very commonly prescribed and can worsen psoriasis⁸. Psoriatic rashes are the most common dermatologic side-effect of beta blockers and are commonly in patients with no personal or family history of psoriasis¹¹. Topical beta blockers, including those for glaucoma, have also been associated¹². Dermatologic manifestations typically begin as early as 1 month after initial treatment and can arise as late as 2 years into therapy¹³. Skin manifestations tend to resolve or significantly improve within days to weeks after discontinuation of the medication and recur within days of re-

challenge¹¹. Some psoriatic rashes associated with beta blockers do not completely resolve¹⁴. The pathophysiology of beta blocker induced psoriasis is complex and not fully elucidated but appears to involve cyclic adenosine monophosphate (cAMP), lymphocyte transformation, intracellular protein metabolism, intracellular calcium changes, macrophage abnormalities, and abnormal neutrophil function⁴. The management of beta blocker induced psoriatic rashes involves withdrawing the medication if possible and initiating or adjusting conventional psoriatic treatments¹⁵.

Antibiotics are also commonly associated with psoriasis. The most commonly associated class is the tetracycline family although macrolides and penicillin have also been linked¹⁶. Pencillins have been noted to trigger the pustular variant of psoriasis¹⁷. Those with a personal or family history as well as those with certain HLA-genotypes such as HLA-B13, B17, and B27 appear to be at the greatest risk of this sort of reaction.⁴

NSAIDs are also commonly associated with dermatologic manifestations of psoriasis⁵. Naproxen has been the most commonly reported and both orally and topically administered NSAID's have been associated¹⁸. NSAID-associated psoriatic rashes tend to occur fairly quickly after initiating therapy frequently within days to weeks.⁴ As with other types of drug-induced dermatologic processes, most cases resolve or dramatically improve shortly after discontinuing the offending agent¹⁹.

Several hundred other medications have been associated with exacerbating or causing psoriatic rashes⁷. These include lithium, ace-inhibitors, anti-malarials, interferons, benzodiazepines, gemfibrozil, cimetidine, amiodarone, fluoxetine, and digoxin¹⁸. A personal or family history of psoriasis and age over 50 both increase the risk of cutaneous reactions¹⁹. Careful consideration of withdrawal of the potential offending agent is sometimes necessary to investigate a true cause and effect relationship²⁰.

Dietary factors also can trigger psoriatic reactions². For example, iodine contained in intravenous contrast or foods have both been associated with psoriasis and bullous pemphigoid²¹. Shellfish intake has been suggested as a possible trigger for psoriatic rashes²². Additionally, hypovitaminosis D has been associated with vitiligo and psoriasis²³. Dietary supplementation with omega-3 fatty acids has been associated with clinical improvement in the

dermatologic manifestations of psoriasis²⁴. Various supplements have been tested to see how they impact psoriasis with mixed results²⁵. Hypocalcaemia appears to be significant risk factor for psoriatic exacerbations²⁶. and alcohol consumption increases the risk of exacerbations in several studies²⁷.

A detailed medical history suggested multiple possible triggers for this patient's psoriatic exacerbation. They included his recent use of an antibiotic (azithromycin), the recent increase in his beta blocker dose, increased intake of alcohol, and his recent consumption of iodine-containing seafood. Increased Carvedilol was important so it was not adjusted. We recommended minimizing intake of iodine-containing foods and alcohol. He remained off of antibiotics in the subsequent weeks and within two months his psoriasis had dramatically subsided and was back under optimal control, without adjusting his psoriasis regimen.

REFERENCES

1. **Naldi L.** Epidemiology of psoriasis. *Curr Drug Targets Inflamm Allergy*. 2004 Jun;3(2):121-8. Review. PubMed PMID: 15180464.
2. **Raychaudhuri SP, Farber EM.** The prevalence of psoriasis in the world. *J Eur Acad Dermatol Venereol*. 2001 Jan;15(1):16-7. PubMed PMID: 11451313.
3. **Boehncke WH, Boehncke S, Schön MP.** Managing comorbid disease in patients with psoriasis. *BMJ*. 2010 Jan 15;340:b5666. doi: 10.1136/bmj.b5666. Review. PubMed PMID: 20080817.
4. **Tsankov N, Angelova I, Kazandjieva J.** Drug-induced psoriasis. Recognition and management. *Am J Clin Dermatol*. 2000 May-Jun;1(3):159-65. Review. PubMed PMID:11702297.
5. **Fry L, Baker BS.** Triggering psoriasis: the role of infections and medications. *Clin Dermatol*. 2007 Nov-Dec;25(6):606-15. Review. PubMed PMID: 18021899.
6. **Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, Plantin P, Claudy A, Delavierre C, Vaillant L, et al.** Acute generalized exanthematous pustulosis. *Analysis of 63 cases. Arch Dermatol*. 1991 Sep;127(9):1333-8. PubMed PMID: 1832534.
7. **Rongioletti F, Fiorucci C, Parodi A.** Psoriasis induced or aggravated by drugs. *J Rheumatol Suppl*. 2009 Aug;83:59-61. doi: 10.3899/jrheum.090227. PubMed PMID:19661544.
8. **Jensen H, Mikkelsen I, Wadskov F, Sondergaard J.** Cutaneous reactions to propranolol. *Acta Med Scand*. 1976;199:363-8.
9. **Sehgal VN, Dogra S, Srivastava G, Aggarwal AK.** Psoriasiform dermatoses. *Indian J Dermatol Venereol Leprol*. 2008 Mar-Apr;74(2):94-9. Review. PubMed PMID:18388363.
10. **Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM.** Drugs in exacerbation of psoriasis. *J Am Acad Dermatol*. 1986 Nov;15(5 Pt 1):1007-22. Review. PubMed PMID: 2878015.

11. **Waqar S, Sarkar PK.** Exacerbation of psoriasis with beta-blocker therapy. *CMAJ.* 2009 Jul 7;181(1-2):60. doi: 10.1503/cmaj.081433. PubMed PMID: 19581619; PubMed Central PMCID: PMC2704418.
12. **O'Brien M, Koo J.** The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. *J Drugs Dermatol.* 2006 May;5(5):426-32. Review. PubMed PMID: 16703778.
13. Glass LR, Nguyen M, Winn BJ, Schrier A. Timolol drops causing reversible psoriatic fingernail changes. *JAMA Ophthalmol.* 2013 Sep;131(9):1134. doi:10.1001/jamaophthalmol.2013.1579. PubMed PMID: 24030331.
14. **Heng MC, Heng MK.** Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. *Int J Dermatol.* 1988 Nov;27(9):619-27. PubMed PMID: 2906634.
15. **Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R.** Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2008 May;58(5):826-50. doi:10.1016/j.jaad.2008.02.039. PubMed PMID: 18423260.
16. **Wright AL, Colver GB.** Tetracyclines--how safe are they? *Clin Exp Dermatol.* 1988 Mar;13(2):57-61. Review. PubMed PMID: 3063416.
17. **Katz M, Seidenbaum M, Weinrauch L.** Penicillin-induced generalized pustular psoriasis. *J Am Acad Dermatol.* 1987 Nov;17(5 Pt 2):918-20. PubMed PMID: 3680681.
18. **Grau R.** Drug-induced psoriasis – A retrospective chart review performed at the University of Oklahoma Department of Dermatology. *J Am Acad Dermatol.* 2008; 58:AB127.
19. **Cohen AD, Bonne DY, Reuveni H, Vardy DA, Naggan L, Halevy S.** Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. *Acta Derm Venereol.* 2005;85(4):299-303. PubMed PMID: 16191849.
20. **Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC.** Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. *J Cutan Pathol.* 2001 Mar;28(3):113-9. Review. PubMed PMID: 11168761.
21. **Kluk J, Goulding JM, Bhat J, Finch TM.** Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. *Clin Exp Dermatol.* 2011 Dec;36(8):871-3. doi: 10.1111/j.1365-2230.2011.04102.x. Epub 2011 May 30. PubMed PMID: 21623885.
22. **Lakdawala N, Babalola O 3rd, Fedeles F, McCusker M, Ricketts J, Whitaker-Worth D, Grant-Kels JM.** The role of nutrition in dermatologic diseases: facts and controversies. *Clin Dermatol.* 2013 Nov-Dec;31(6):677-700. doi: 10.1016/j.clindermatol.2013.05.004. PubMed PMID: 24160272.
23. **Finamor DC, Sinigaglia-Coimbra R, Neves LC, Gutierrez M, Silva JJ, Torres LD, Surano F, Neto DJ, Novo NF, Juliano Y, Lopes AC, Coimbra CG.** A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. *Dermatoendocrinol.* 2013 Jan 1;5(1):222-34. doi: 10.4161/derm.24808. PubMed PMID: 24494059; PubMed Central PMCID: PMC3897595.
24. **Guida B, Napoleone A, Trio R, Nastasi A, Balato N, Laccetti R, Cataldi M.** Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. *Clin Nutr.* 2013 Sep 28. pii: S0261-5614(13)00248-3. doi: 10.1016/j.clnu.2013.09.010. [Epub ahead of print] PubMed PMID: 24120032.
25. **Skoza N, Proietti I, Bernardini N, La Viola G, Nicolucci F, Pampena R, Tolino E, Zuber S, Mancini MT, Soccodato V, Balduzzi V, Potenza C.** Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNF α treatment. *G Ital Dermatol Venereol.* 2013 Dec;148(6):661-5. PubMed PMID: 24442048.
26. **Qadim HH, Goforoushan F, Nejad SB, Goldust M.** Studying the calcium serum level in patients suffering from psoriasis. *Pak J Biol Sci.* 2013 Mar 15;16(6):291-4. PubMed PMID: 24498793.
27. **Cassano N, Vestita M, Apruzzi D, Vena GA.** Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. *Int J Dermatol.* 2011 Nov;50(11):1323-31. doi:10.1111/j.1365-4632.2011.05100.x. Review. PubMed PMID: 22004481.

Submitted on February 25, 2014